Objective To investigate the mechanism by which Scutellaria barbata D.Don water extract(SBW)inhibits lung metastasis of breast cancer by regulating the immune microenvironment.Methods A mouse model of lung metastasis was established using 4T1 breast cancer cells.Mice were divided into a control group(n=6)and an SBW treatment group(n=6).The effect of SBW on tumor growth was assessed by measuring the volume of the primary tumor,and the inhibitory effect on lung metastasis was evaluated by observing the number and area of metastatic nodules in lung tissue using H&E staining.Flow cytometry was used to analyze changes in the composition of immune cells in the tumor,peripheral blood,and lung tissue.Results Compared with the control group,the SBW treatment group inhibited the growth of the primary tumor(P<0.01)and reduced the number and area of lung metastatic nodules(P<0.01).Flow cytometry analysis showed that after SBW treatment,the numbers of CD86+macrophages(P<0.001)and polymorphonuclear myeloid-derived suppressor cells(PMN-MDSCs)(P<0.05)in the tumor tissue were increased.In lung tissue,the numbers of CD86+macrophages,natural killer T(NKT)cells,natural killer(NK)cells,and PMN-MDSCs were also elevated(P<0.05).Meanwhile,the numbers of regulatory T cells(Tregs)(P<0.05),CD206+macrophages(P<0.01),and monocytic myeloid-derived suppressor cells(M-MDSCs)(P<0.05)in both tumor and lung tissues were decreased.Conclusion SBW inhibits the breast cancer growth and lung metastasis by regulating the recruitment and distribution of immune cells in the tumor,peripheral blood,and lung tissue,thereby enhancing anti-tumor immune responses and reducing immune suppression.

Polymyxin B, which is a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections, became available in China in Dec. 2017. As dose adjustments are based solely on clinical experience of risk toxicity, treatment failure, and emergence of resistance, there is an urgent clinical need to perform therapeutic drug monitoring (TDM) to optimize the use of polymyxin B. It is thus necessary to standardize operating procedures to ensure the accuracy of TDM and provide evidence for their rational use. We report a consensus on TDM guidelines for polymyxin B, as endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society. The consensus panel was composed of clinicians, pharmacists, and microbiologists from different provinces in China and Australia who made recommendations regarding target concentrations, sample collection, reporting, and explanation of TDM results. The guidelines provide the first-ever consensus on conducting TDM of polymyxin B, and are intended to guide optimal clinical use.
Humans ; Anti-Bacterial Agents/therapeutic use* ; China ; Drug Monitoring/methods* ; Polymyxin B ; Practice Guidelines as Topic